Cargando…
667. Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent NonFusion Replication Inhibitor of Respiratory Syncytial Virus
BACKGROUND: Respiratory syncytial virus (RSV) infection presents a significant health challenge in young children, elderly and immunocompromised patients. To date, there are no effective treatments available. EDP-938 was designed to meet this unmet medical need and is currently in Phase 2 clinical t...
Autores principales: | Jiang, Li-Juan, Xu, Lisha, Huang, Meng, Zhang, Shucha, Li, Yang, Zang, Indy, Kibel, Jonathan, Adams, Madison, Labrecque, Noelle, Rhodin, Michael, McAllister, Nicole, Lin, Kai, Jong Kim, In, Sun Or, Yat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811274/ http://dx.doi.org/10.1093/ofid/ofz360.735 |
Ejemplares similares
-
EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model
por: Rhodin, Michael H. J., et al.
Publicado: (2021) -
923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study
por: Levene, Rachel E, et al.
Publicado: (2023) -
EDP-938, un nuevo antiviral con actividad inhibidora frente a la nucleoproteína del virus respiratorio sincitial
por: Reina, Jordi, et al.
Publicado: (2022) -
A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020) -
EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1988)